Championing a Better Life: Deep Science Ventures and Parkinson’s UK Forge New Pathways in Parkinson’s Therapeutics

Championing a Better Life: Deep Science Ventures and Parkinson’s UK Forge New Pathways in Parkinson’s Therapeutics 

With over 12 million individuals anticipated to live with the condition globally by 2040, the partnership aims to accelerate identifying and progressing novel curative therapies. 

[ London - 20 of December, 2023 ] In a landmark collaboration that marries scientific prowess with an unwavering dedication to improving patient lives, Deep Science Ventures (DSV), an avant-garde venture creator headquartered in London, has announced a pioneering partnership with Parkinson’s UK, the leading charity driving better care, treatments, and quality of life for those affected by Parkinson’s.

A Groundbreaking Partnership for Parkinson's Therapeutics

This strategic alliance is set to merge DSV’s unique invention method with Parkinson’s UK’s rich insights into patient care, igniting the creation of a new, dedicated company. The aim is to propel the most innovative and efficient therapeutic approach into real-world application, funded by the transformative Parkinson's Virtual Biotech initiative - Parkinson’s UK investment arm. 

The Urgent Call for Innovation

With over 6 million individuals living with Parkinson’s today, and projections soaring to 12 million globally by 2040, the condition presents escalating challenges. Patients are battling a spectrum of symptoms that current treatments can barely temper - from dementia to insomnia, pain, tremors, involuntary muscle contractions, loss of speech and loss of mobility. Whilst current treatments offer some symptomatic respite, no therapies are able to alter disease progression. Fueled by an urgent need, this partnership heralds a beacon of hope for halting and reversing the course of Parkinson’s. 

Unleashing a Wave of Novel Therapies

With Parkinson’s UK wealth of experience in patient support and the scientific rigour of DSV’s outcome-focused innovation method, the alliance is set to unleash a multitude of new therapeutic concepts. Laura Fletcher of DSV articulates the shared enthusiasm, “Parkinson’s is an area with huge unmet patient need where we feel DSV’s approach has the potential for major impact. We are thrilled that Parkinson’s UK shares this ambitious vision and has joined us to drive the creation of new curative approaches”

Arthur Roach of Parkinson's Virtual Biotech adds, “This partnership stands as a testament to our relentless pursuit of life-changing therapies.”

The Path Ahead

In its nascent phase, DSV and Parkinson’s UK will be jointly exploring and pinpointing the focal therapeutic area for venture creation. Subsequently, DSV will recruit a leading expert as Founder-in-Residence to spearhead the design of new therapeutic strategies and progress into creating a new start-up to take forward the most promising approach into proof-of-concept studies.

Deep Science Ventures and Parkinson’s UK are not just on the brink of innovation; they are defining it—driving towards a future where the promise of a better life for those with Parkinson’s is not just a hope, but a reality.

For more information, or to explore engagement opportunities with this forward-thinking initiative, interested parties are invited to reach out to DSV at pharma@deepscienceventures.com.

-END-

About Deep Science Ventures:

Deep Science Ventures is creating a future where humanity and the planet can thrive, combining available scientific knowledge and founder-type scientists into high-impact ventures. Deep Science Ventures operates in 4 sectors: Agriculture, Climate, Computation and Pharmaceuticals, tackling the challenges defining those areas by taking a first-principles approach and partnering with leading institutions. 

DSV has launched more than 35 deep tech ventures, attracted over £100M in funding and amassed a portfolio value of more than a quarter billion pounds. By deploying its proprietary venture creation methodology, DSV’s startups boast an 83% survival rate from their first two to five years, compared to only 30% industry average. 

Note to Editors:

For additional information, exclusive interviews, or to arrange a meeting, please contact Laura Fletcher at the above email. High-resolution images and detailed project briefs are available upon request.